Showing 3641-3650 of 7135 results for "".
- SCRATCH-AD: Rapid-Onset Anti-Itch and Anti-Inflammatory Effects of Ruxolitinib Creamhttps://practicaldermatology.com/news/scratch-ad-rapid-onset-anti-itch-and-anti-inflammatory-effects-of-ruxolitinib-cream/2484591/Results from the SCRATCH-AD study suggested that ruxolitinib cream 1.5% provided itch relief, as well as broader improvements in atopic dermatitis (AD) severity The SCRATCH-AD study evaluated how quickly ruxolitinib 1.5% cream
- Stapokibart Shows Efficacy and Safety in Elderly Patients With ADhttps://practicaldermatology.com/news/stapokibart-shows-efficacy-and-safety-in-elderly-patients-with-ad/2484589/This post hoc analysis evaluated the efficacy and safety of stapokibart, an anti–IL-4Rα monoclonal antibody, in elderly adults with moderate-to-severe atopic dermatitis—a population often characterized by more complex inflammatory signatures and comorbidities. The
- Tralokinumab Maintains Efficacy in Hand AD Through 32 Weekshttps://practicaldermatology.com/news/tralokinumab-maintains-efficacy-in-hand-ad-through-32-weeks/2484484/LEO Pharma has announced positive 32-week topline results from its ADHAND trial, a phase 3b study evaluating tralokinumab in adults with moderate-to-severe atopic dermatitis (AD) with hand involvement. According to a press rele
- Arcutis Completes Enrollment for INTEGUMENT-INFANT Studyhttps://practicaldermatology.com/news/arcutis-completes-enrollment-for-integument-infant-study/2484474/Arcutis Biotherapeutics announced the completion of patient enrollment for the INTEGUMENT-INFANT phase 2 study, according to a press release from the company. Researchers for INTEGUMENT-INFANT will be evaluating ZORYVE® (roflum
- Seborrheic Dermatitis Linked to Systemic Epithelial Barrier Diseases: Analysishttps://practicaldermatology.com/news/seborrheic-dermatitis-linked-to-systemic-epithelial-barrier-diseases-analysis/2484390/Findings from a new retrospective cohort suggest individuals living with seborrheic dermatitis are more likely to have other epithelial barrier diseases such as rosacea, alopecia areata, and celiac disease. Investigators publish
- NICE Recommends First Topical JAK Inhibitor for CHE in England and Waleshttps://practicaldermatology.com/news/nice-recommends-first-topical-jak-inhibitor-for-che-in-england-and-wales/2484333/The National Institute for Health and Care Excellence (NICE) has recommended the reimbursement of Anzupgo® (delgocitinib) cream for adult patients with moderate to severe chronic hand eczema (CHE) who have not responded to,
- Analysis: Fibrotic Skin Diseases Linked to Elevated ASCVD Riskhttps://practicaldermatology.com/news/analysis-fibrotic-skin-diseases-linked-to-elevated-ascvd-risk/2484276/Patients with fibrotic skin diseases may have an elevated risk of atherosclerotic cardiovascular disease (ASCVD), according to new real-world data from the TriNetX platform. The study researchers conducted a retrospective cohort
- Lebrikizumab Maintains Efficacy With Reduced Dosing Intervalhttps://practicaldermatology.com/news/lebrikizumab-maintains-efficacy-with-reduced-dosing-interval/2484255/Long-term data from a 32-week extension of the ADjoin trial suggest that lebrikizumab, an IL-13 inhibitor approved for once-monthly dosing, may maintain clinical efficacy in patients with moderate-to-severe atopic dermatitis (AD) even when administered once every 8
- Dr. Peter Lio Named Fall Clinical Educator of the Yearhttps://practicaldermatology.com/news/dr-peter-lio-named-fall-clinical-educator-of-the-year/2484092/Peter Lio, MD, was presented with the Educator of the Year Award at the 2025 Fall Clinical Dermatology Conference. Dr. Lio is founding director of the Chicago Integrative Eczema Center and a member of Practical Dermatology’s Editorial Board. Dr. Lio spoke at the Fall Clinical Meetin
- Emerging Treatments for CLE Highlighted at Fall Clinicalhttps://practicaldermatology.com/news/emerging-treatments-for-cle-highlighted-at-fall-clinical/2484091/Cutaneous lupus erythematosus (CLE) patients often face long treatment timelines, drug toxicity, and misdiagnoses, but recent advances in mechanism-based agents mark a significant step forward, Lauren Graham, MD, PhD, and Alisa Femia, MD, said during a presentation at the 2025 Fall Clinical Derma